Cargando…

Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study

This case study highlights the dynamic nature of the antibody response to SARS-CoV-2 in a vulnerable subject aged 70 years between 2021 and 2023. This individual had been vaccinated with six doses of the ancestral (Wuhan-Hu-1) COVID-19 vaccine and had a breakthrough infection 126 days after receivin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanokudom, Sitthichai, Suntronwong, Nungruthai, Duangchinda, Thaneeya, Wanlapakorn, Nasamon, Poovorawan, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Allergy/Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507991/ https://www.ncbi.nlm.nih.gov/pubmed/37731681 http://dx.doi.org/10.7759/cureus.45531

Ejemplares similares

Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
por: Suntronwong, Nungruthai, et al.
Publicado: (2023)

SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
por: Yorsaeng, Ritthideach, et al.
Publicado: (2023)

Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens
por: Bureerug, Teeraporn C., et al.
Publicado: (2023)

Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Respiratory syncytial virus, human metapneumovirus, and influenza virus infection in Bangkok, 2016-2017
por: Thongpan, Ilada, et al.
Publicado: (2019)

Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023
por: Chansaenroj, Jira, et al.
Publicado: (2023)

Antibodies to Bordetella pertussis antigens in maternal and cord blood pairs: a Thai cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2017)

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2022)

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
por: Luangdilok, Sutima, et al.
Publicado: (2022)

The Effect of Third Dose of Pfizer/BioNTech and Moderna COVID-19 mRNA Vaccines on IgG Antibody Titers
por: Khuc, Thao A, et al.
Publicado: (2023)

The Impact of Timing of Pertussis Vaccination During Pregnancy on Infant Antibody Levels at Birth: A Multi-Country Analysis
por: Gomme, Justin, et al.
Publicado: (2022)

Administration of the Second Dose of mRNA COVID-19 Vaccine to a Woman With Immediate Reaction to the First Dose
por: Apostolidou, Evaggelia, et al.
Publicado: (2023)

COVID-19 Antibodies in Vaccinated Healthcare Workers: The Security Currency
por: Ammar, Ali, et al.
Publicado: (2022)

Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination
por: Wanlapakorn, Nasamon, et al.
Publicado: (2016)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

The impact of COVID-19 and control measures on public health in Thailand, 2020
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022)

Seroprevalence of an antibody against diphtheria, tetanus, and pertussis among the elderly in Khon Kaen, Thailand
por: Chinchai, Teeraporn, et al.
Publicado: (2019)

Implementation of hepatitis B vaccine in high-risk young adults with waning immunity
por: Posuwan, Nawarat, et al.
Publicado: (2018)

Rotavirus infection in children in Southeast Asia 2008–2018: disease burden, genotype distribution, seasonality, and vaccination
por: Lestari, Fajar Budi, et al.
Publicado: (2020)

Strategies to Prevent Mother-to-child Transmission of Hepatitis B Virus
por: Sintusek, Palittiya, et al.
Publicado: (2023)

Anti-spike Antibody Status in Pre-vaccinated Healthy Participants and Rheumatoid Arthritis Patients During the Third Wave of COVID-19
por: Eerike, Madhavi, et al.
Publicado: (2023)

Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants
por: Hu, Siyuan, et al.
Publicado: (2022)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Immune Thrombocytopenia in Previously Healthy Individuals Following SARS-CoV-2 Vaccination (COVID-19 Immunization): A Descriptive Research of 70 Instances With a Focus on Biomarkers, Predictive Outcomes, and Consequences
por: Sharma, Kamal, et al.
Publicado: (2022)

Antibodies to Brewer's Yeast in Rheumatoid Arthritis
por: Lichtenstein, Jack R, et al.
Publicado: (2019)

Characterizing genetic and antigenic divergence from vaccine strain of influenza A and B viruses circulating in Thailand, 2017–2020
por: Suntronwong, Nungruthai, et al.
Publicado: (2021)

Successful Desensitization to mRNA COVID-19 Vaccine in a Case Series of Patients With a History of Anaphylaxis to the First Vaccine Dose
por: AlMuhizi, Faisal, et al.
Publicado: (2022)

COVID-19 Antibody Response in Patients with Thalassemia
por: Kumari, Nidhi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sh9c9etcgc25k4d7jk6nb6eu9i